Biocon
Trisha Durant is a highly experienced professional in commercial strategy and business development, currently serving as the Head of Europe for Commercial Strategy & Business Development at Biocon since July 2023. Prior to this role, Trisha was the Vice President of Partnerships & Business Development at Vamstar, focusing on strategic partnerships and healthcare technology. Trisha's extensive background includes over a decade at McKesson in various senior director roles, managing global private label business development and partnership management. Trisha also held positions at Gap Inc. and Ernst & Young, with a strong educational foundation in economics and an MBA in finance and strategy from the University of California, Berkeley, and the University of California, Davis respectively.
This person is not in any teams
This person is not in any offices
Biocon
22 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.